BridgeBio Oncology Therapeutics, Inc. (Bbot) announced that its innovative therapy Bbo-11818, for adult patients with advanced KRAS-mutated pancreatic ductal adenocarcinoma, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chip giant makes a move in the quantum track: Intel (INTC.US) acquires startup Classiq to build a full-stack quantum business
Intel has announced the acquisition of Israeli quantum startup Classiq for an undisclosed amount, with the deal expected to be completed in the first half of 2027. Liwu Chen stated that they will develop a full-stack quantum computing business.
$17 billion acquisition emerges: DoorDash (DASH.US) in advanced talks to acquire Instacart, official announcement expected as early as this week
DoorDash plans to acquire Instacart's parent company Maplebear for approximately $17 billions, with an official announcement expected as early as this week. Maplebear shares rose 7.9%, while DoorDash fell 6.1%. The negotiations may fall through.
Fed and ECB decisions fall a day apart for a Euro under 1.12
Strong demand for AI chip design! Cadence Design Systems (CDNS.US) Q3 revenue up 22% year-on-year, full-year guidance raised
Kongteng Electronics reported Q3 revenue of $1.633 billions, representing a year-on-year increase of 22%, higher than the $1.339 billions recorded in the same period last year.
Crypto prices
More
